GlobeNewsWire · JNJ · October 25, 2026

Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer

Get the app for more

Explore stock news, insights and company research.